BDNF and Parkinson disease: Wang et al. (2016) demonstrated that 5-azacytidine treatment in the MPTP mouse model of PD resulted in the significant demethylation of the BDNF promoter (45% reduction), leading to a 2.3-fold increase in BDNF expression [86].